Frangoul and colleagues: CRISPR–Cas9 editing for sickle-cell disease and β-thalassemia

What changed

Therapeutic genome editing showed early human feasibility in two monogenic blood diseases.

Scientific scope

Exact 26-author report and its two patients/follow-up; later cohorts and approval excluded.

Evidence

The linked sources identify this contribution and its scope. WRS has not independently reconstructed the scientific claims. The record is the exact 2021 NEJM report of two treated patients and its stated follow-up. The CRISPR mechanism paper, later trial cohorts, regulatory approvals, manufacturing and claims of universal cure remain separate.

Contributors

• The named authors listed in the linked research record · SCIENCE: Complete source byline retained in the research record; this collective display does not merge person identities or measure labor shares.

• Frangoul et al., CRISPR–Cas9 editing for sickle-cell disease and β-thalassemia
• Crossref record for CRISPR hemoglobinopathy report

Provisional WRS assessment, edition 2026-10-16.1. Independent expert calibration is pending. This grade does not certify correctness or assign ownership.

Full scientific record · Browse contribution grades · Request a correction